US IPO Pipeline SEC S-1 Filings — June 24, 2026

24-06-2026

Liminatus Pharma, Inc. filed an S-1 registration statement on June 24, 2026, for a proposed best-efforts public offering of common stock and pre-funded warrants. The company has a history of significant related-party loans and notes, including from Feelux Co., Ltd., Valetudo, Prophase, Hana, Ewon, CarTcellkor, and Amantes, and has accumulated substantial deficits (retained earnings of -$112,375,356 as of March 31, 2026). The filing also details a CD47 license and development agreement with Innobation, but the company remains pre-revenue with no disclosed revenue figures.

• · The S-1 filing is for a best-efforts public offering of common stock and pre-funded warrants.
• · The company has a par value of $0.25 per common share and $1.50 per preferred share.
• · Total assets as of March 31, 2026, were $117,500,000.
• · The filing includes extensive related-party loans from entities such as Feelux Co., Ltd., Valetudo, Prophase, Hana, Ewon, CarTcellkor, and Amantes, with various loan dates from 2018 to 2026.
• · A CD47 license and development agreement with Innobation is referenced for the periods ending March 31, 2025, and March 31, 2026.
• · The company has no disclosed revenue, indicating it is pre-revenue.

24-06-2026

Hoya Acquisition Corp. I filed an S-1 registration statement on June 24, 2026, for an initial public offering of units consisting of ordinary shares. The company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The filing details the proposed offering size, use of proceeds, and risk factors associated with the SPAC structure.

• · The filing is an S-1 registration statement under the Securities Act of 1933.
• · The SEC file number is 333-296983.
• · The company is incorporated in the Cayman Islands (state of incorporation E9).
• · The fiscal year ends on December 31.
• · The business address is 6210 Wilshire Blvd Ste 200, Los Angeles, CA 90048.
• · The filing date is June 24, 2026, and the document date is June 10, 2026.

24-06-2026

Somnigroup International Inc. filed an S-4 registration statement on June 24, 2026, in connection with its proposed merger with Leggett & Platt, Incorporated. Under the merger agreement dated April 13, 2026, each share of Leggett & Platt common stock will be converted into 0.1455 shares of Somnigroup common stock, and Leggett & Platt will become a wholly owned subsidiary of Somnigroup. The merger requires approval by at least two-thirds of Leggett & Platt's outstanding shares, and the combined company will retain Somnigroup's Dallas headquarters while Leggett & Platt operates as a separate business unit.

• · Merger sub (Sparrow Unity Corporation) was incorporated on April 9, 2026, solely for the merger.
• · Leggett & Platt common stock will be delisted from NYSE and deregistered under the Exchange Act after the merger.
• · No fractional shares of Somnigroup common stock will be issued; fractional interests will be cashed out based on sale of excess whole shares.
• · The exchange ratio of 0.1455 is fixed and will not adjust for market price changes, except for stock splits or similar events.
• · Leggett & Platt shareholders must vote by telephone, internet, or mail; shares held in street name require broker instructions.
• · The special meeting will be held virtually via live webcast on a date to be determined in 2026.
• · Abstentions, broker non-votes, and failures to vote will count as votes AGAINST the merger proposal.
• · The merger-related compensation proposal requires a majority of voting power present or represented at the meeting.

24-06-2026

iSpecimen Inc. filed an S-1 registration statement for an IPO, reporting a net loss of $10,487,532 for FY2025 (improved from $12,497,805 in FY2024) and a net loss of $2,275,221 for Q1 2026 (wider than $1,658,396 in Q1 2025). Revenue fell sharply to $1,928,998 in FY2025 from $9,291,115 in FY2024, and continued declining to $156,009 in Q1 2026 from $1,057,510 in Q1 2025. The company has an accumulated deficit of $84,625,370 as of March 31, 2026, and its auditors have expressed substantial doubt about its ability to continue as a going concern.

• · Working capital (current assets less deferred offering costs and less current liabilities) was negative $2,115,634 as of March 31, 2026.
• · One customer accounted for approximately 20% of revenue in FY2025; in Q1 2026, one customer represented approximately 54% of revenue.
• · A material weakness in internal control over financial reporting was identified related to sales tax compliance; remediation measures are underway.
• · The company was founded in 2009, first commercial sale in 2012, and began generating revenue in 2016.
• · The company expects to continue incurring losses and may need additional capital; there is substantial doubt about its ability to continue as a going concern.